Companies planning to open to the public during the pandemic should review potential claims related to COVID-19 and take preemptive measures.
The ongoing COVID-19 pandemic raises many questions about safety and liability...more
New York State has issued guidance regarding businesses exempt from the order, but has yet to clarify its regulations’ interplay with local orders and federal guidance.
As part of the State of New York’s continued response...more
The Order requires many businesses to close, but allows essential industries to continue operating, and permits employees to work remotely, as applicable.
On March 23, 2020, Massachusetts Governor Charles D. Baker issued...more
The Fairness in Class Action Litigation Act, passed by the House of Representatives on March 9, 2017, may significantly change how class action cases proceed under Rule 23.
Key Points:
..The Act addresses a range of...more
FDA’s delay on the final version of generic labelling rules until April 2017 means both branded and generic drug manufacturers face continued uncertainty.
The U.S. Food and Drug Administration (FDA) recently announced it...more
6/7/2016
/ Failure To Warn ,
Food and Drug Administration (FDA) ,
Foreseeability ,
Generic Drugs ,
Innovator Liability ,
Manufacturers ,
Pharmaceutical Industry ,
PLIVA v Mensing ,
Preemption ,
Prescription Drugs ,
Proposed Regulation ,
Warning Labels